Zentalis Pharmaceuticals, Inc.
ZNTL
$4.15
-$0.01-0.12%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 26.78% | 25.82% | 33.54% | 69.56% | -579.53% |
| Total Depreciation and Amortization | -42.37% | -50.47% | -50.16% | -51.07% | -19.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -78.18% | -62.17% | -75.80% | -99.15% | 129.10% |
| Change in Net Operating Assets | -141.51% | 80.53% | 83.88% | -162.49% | 111.29% |
| Cash from Operations | -0.98% | 22.07% | 38.78% | 1.23% | 37.21% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 767.69% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.75% | 0.11% | -41.30% | -13.85% | -34.29% |
| Cash from Investing | -25.85% | 0.51% | -41.30% | -11.92% | -34.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 75.13% | -- | 25.00% | -100.00% | -23.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -694.18% | -- | 25.00% | -100.00% | 2,600.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -150.64% | 58.53% | -65.66% | -576.56% | -16.18% |